JPMorgan Initiates Hansoh Pharmaceutical (03692.HK) with 'Overweight' Rating and HK$43 Price Target

According to the Zhishang Finance APP, J.P. Morgan released a research report stating that it has initiated coverage on Hansoh Pharma (03692.H) with an "Overweight" rating, setting a target price of HK$43 based on the discounted cash flow method. J.P. Morgan noted that Hansoh has transformed into an innovation-driven leader in recent years, with the sales contribution from innovative products surging from 18% in 2020 to 77% in 2024, representing a compound annual growth rate of 57%. The firm believes that Hansoh is one of the most advantaged companies among China's biopharmaceutical enterprises and can benefit from the trend of licensing collaborations.

Morgan Stanley noted that the supporting factors for Hansoh Pharma include: a strong commitment to R&D, backed by its robust portfolio of commercialized products; a diversified product pipeline covering oncology, immunology, cardiometabolic, and neurology; and a proven track record of successful collaborations with multinational companies. Morgan Stanley expects that sales of innovative drugs and licensing revenue will drive Hansoh Pharma’s revenue and net profit to achieve compound annual growth rates of 12% and 15%, respectively, by 2030.